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Background: The aim was to develop prediction rules that may guide early treatment decisions based on baseline
clinical predictors of long-term unfavorable outcome in juvenile idiopathic arthritis (JIA).
Methods: In the Nordic JIA cohort, we assessed baseline disease characteristics as predictors of the following outcomes
8 years after disease onset. Non-achievement of remission off medication according to the preliminary Wallace criteria,
functional disability assessed by Childhood Health Assessment Questionnaire (CHAQ) and Physical Summary Score (PhS)
of the Child Health Questionnaire, and articular damage assessed by the Juvenile Arthritis Damage Index-Articular (JADI-
A). Multivariable models were constructed, and cross-validations were performed by repeated partitioning of the cohort
into training sets for developing prediction models and validation sets to test predictive ability.
Results: The total cohort constituted 423 children. Remission status was available in 410 children: 244 (59.5%) of these did
not achieve remission off medication at the final study visit. Functional disability was present in 111/340 (32.7%) children
assessed by CHAQ and 40/199 (20.1%) by PhS, and joint damage was found in 29/216 (13.4%). Model performance was
acceptable for making predictions of long-term outcome. In validation sets, the area under the curves (AUCs) in the
receiver operating characteristic (ROC) curves were 0.78 (IQR 0.72–0.82) for non-achievement of remission off medication,
0.73 (IQR 0.67–0.76) for functional disability assessed by CHAQ, 0.74 (IQR 0.65–0.80) for functional disability assessed by
PhS, and 0.73 (IQR 0.63–0.76) for joint damage using JADI-A.
Conclusion: The feasibility of making long-term predictions of JIA outcome based on early clinical assessment is
demonstrated. The prediction models have acceptable precision and require only readily available baseline variables.
Further testing in other cohorts is warranted.
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Juvenile idiopathic arthritis (JIA) is a heterogeneous child-
hood disease, with chronic joint inflammation as the com-
mon feature. The JIA categories differ by the number of
joints affected, and the presence of extra-articular involve-
ment [1]. Disease course and prognosis differ between JIA
categories, but there is also large variability within each* Correspondence: veronika.rypdal@unn.no
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baseline clinical prognostic factors that can predict the se-
verity, course, and long-term outcome of the disease [4, 5].
The primary goal of JIA treatment is to achieve remission
[6]. Early prediction of the disease course for the individual
child can facilitate tailored treatment. There is increasing
evidence for the concept of “the window of therapeutic op-
portunity” in JIA, where early aggressive treatment with bio-
logic agents and/or other disease-modifying anti-rheumatic
drugs (DMARDs) may modify the disease course and im-
prove long-term prognosis [7–9]. On the other hand, it isle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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toxic treatment in children with a favorable prognosis.
Guzman et al. have recently presented a model for
prediction of severe disease course, with outcomes de-
veloped specifically for their study [10]. In a systematic
literature review, Dijkhuizen and Wulffraat state the
need for prospective longitudinal studies of baseline
clinical predictors using standardized validated outcome
measures [4]. In the Nordic JIA cohort, we studied pre-
diction of four established and validated outcomes, and
aimed to construct prediction models that may aid deci-
sion on early aggressive treatment.
Methods
Study population
The initial prospective longitudinal multicenter Nordic
JIA cohort consisted of consecutive children with inci-
dent JIA from 12 participating centers in defined geo-
graphical areas of Denmark, Finland, Norway and
Sweden. All children in these areas with newly diag-
nosed JIA and disease onset in the study periods be-
tween 1 January 1997 and 30 June 2000 were included.
The study was designed to be as close to population-
based as possible, as previously reported [11].
In the current study, 440 children met the criteria of
having a baseline study visit and a final study visit 8 years
after disease onset. Out of these, 17 patients with sys-
temic JIA were excluded, because systemic JIA is consid-
ered to have autoinflammatory rather than autoimmune
disease mechanisms, and the clinical characteristics of
predominantly fever, rash and serositis differs from other
JIA-categories [12].
The baseline study visit was planned 6 months after dis-
ease onset. At this visit, disease activity variables, complete
joint count, physician’s global assessment of disease activ-
ity (physician’s GA) on a 10-cm visual analogue scale
(VAS), patient’s/parent’s global assessment (GA), medica-
tion and blood tests were registered [13]. Disease onset
was defined as the time of presentation of symptoms of
active arthritis, and the JIA categories were determined ac-
cording to the International League of Associations for
Rheumatology (ILAR) criteria [14].
Outcomes
At follow up, we evaluated 4 outcomes: (1) the main
outcome was non-achievement of remission off medica-
tion, chosen as the best available validated measure of
an adverse disease state over time. This included active
disease, inactive disease of less than 12 months of dur-
ation, and clinical remission on medication (according
to the preliminary Wallace criteria) [15, 16]. For the re-
mainder of the paper, not in remission or non-
achievement of remission refers to non-achievement of
remission off medication unless otherwise specified; (2)and (3) functional disability was evaluated using the
Childhood Health Assessment Questionnaire (CHAQ),
and the Child Health Questionnaire Parent form (CHQ-
PF50), aiming to achieve a broad evaluation of functional
disability using both the JIA-specific CHAQ and the
generic CHQ-PF50 instruments. CHAQ addresses func-
tional ability in different activities of everyday life [17].
The CHAQ was completed by children of age >9 years,
and otherwise by their parents, and the corresponding
Health Assessment Questionnaire (HAQ) by participants
> 18 years of age. From this point on in the text, CHAQ
will refer to both the CHAQ and HAQ scores. The
CHQ-PF50 consists of 50 items and 12 domains asses-
sing health-related quality of life, yielding a physical
summary score (PhS) and a psychological summary
score (PsS) [17]. PhS ranges from 0 to 100, with a higher
score indicating better functional ability; and (4) joint
damage was assessed using the Juvenile Arthritis Dam-
age Index of articular damage (JADI-A) ranging from 0
to a maximum of 72, where 36 joints, or joint groups,
are scored 0 for no damage, 1 for partial damage, or 2
for severe damage [18]. All 4 outcomes were dichoto-
mized; remission was dichotomized into clinical remis-
sion (those achieving remission without medication),
and non-achievement of remission off medication (those
not achieving remission or achieving remission on medi-
cation), CHAQ and JADI-A into score = 0, indicating no
functional disability or no joint damage, and positive
score >0, PhS into good functional ability, defined as
score ≥40, and functional disability <40. This latter cut-
off level is based on a reference score of 40 being one
standard deviation below the mean score of healthy chil-
dren in the USA [19].
Laboratory tests
Antinuclear antibodies (ANA) and rheumatoid factor
(RF) were tested at least twice with a minimum of 3
months apart. ANA was analyzed by immunofluores-
cence on Hep-2 cells. Tests were interpreted accord-
ing to cutoff values of the local immunological
laboratories. HLA-B27 was analyzed using standard-
ized methods [20]. C-reactive protein (CRP) was mea-
sured with immunoassays, with values <10 mg/L
considered normal.
Statistics
Conventional descriptive statistics (absolute numbers,
median, 1st and 3rd quartile, and percentage) were
used to describe demographics and clinical character-
istics. Univariate logistic regression was performed to
assess baseline variables as predictors for each out-
come. Variables that were significant at p < 0.05 in the
univariate analysis were considered as candidates in a
prediction model.
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models were constructed using a combination of prede-
fined core variables, and additional variables selected using
a forward stepwise selection method. Since the predictive
ability of the models is assessed using cross-validation, the
conventional limitations related to the screening of a large
number of covariates in multivariable models are evaded
[21]. Cross-validation controlled for overfitting of the data
(internal validation), and the degree of overfitting is
reflected in the performance in validation sets.
Clinical characteristics included in the Wallace
provisional criteria for remission were a priori included in
the prediction models; the cumulative active joint count,
erythrocyte sedimentation rate (ESR), CRP, physician’s GA,
and morning stiffness [22]. Uveitis activity applies only to a
minority of the cohort and was therefore not included. The
additional baseline variables were included in a stepwise
fashion if they contributed to the multivariable model with
p < 0.05 when included. Symmetric joint involvement was
not considered a candidate predictor as it correlates
strongly with the specific joint involvement (Fig. 1). To en-
sure model simplicity the total number of variables was not
allowed to exceed 10. Once the set of variables were se-
lected, the model coefficients βi for each predictor variableFig. 1 Correlations between baseline variables. Lines are drawn
only between pairs of baseline variables for which the sample
Spearman correlation coefficient is ≥ 0.50. Baseline variables
without correlation ≥0.50 are not included in the figure. RF,
rheumatoid factor; VAS, visual analogue scale; GA, global
assessment; CHAQ, Childhood Health Assessment Questionnairexi were estimated using multivariable logistic regression,
and the probability of unfavorable outcome was given as:
P ¼ 1= 1þ e−A ;where A ¼ β0 þ β1x1 þ…þ βnxn:
For each of the four outcomes, cross-validation of the
method was performed by partitioning the cohort ran-
domly in training sets consisting of three quarters of the
patients (N = 317) and validation sets consisting of one
quarter of the patients (N = 106). In each realization of
the random partitioning we constructed prediction
models using the algorithm described above, using only
the training set to select variables and estimate coeffi-
cients. For each of the patients in the corresponding val-
idation set the multivariable logistic model provides a
probability of the unfavorable outcome. By comparing
the predicted probability of unfavorable outcome with
the actual outcome at the final study visit, the receiver
operating characteristic (ROC) curve was computed, and
the area under the curve (AUC) was estimated. The me-
dian AUC with interquartile range (IQR) was estimated
from 100 realizations of the random partitioning of the
cohort. For each step in the cross-validation we omitted
any patients where the outcome or the required pre-
dictor variables were not available.
Finally, in our cohort we tested the prediction model
for severe disease course developed by Guzman et al.
[10]. We tested Guzman’s model using the 4 outcome
measures described above, i.e. not the outcomes for
which their model was constructed. The analysis was
performed using the software packages STATA version
14, and Wolfram Mathematica version 11.1.1.0.
Ethical considerations
Approvals from medical research ethical committees and
data protection authorities were granted according to the
regulations of each participating country. Written in-
formed consent was obtained from parents of children
aged < 16 years, and from the children themselves if aged
≥ 16 years of age.
Results
The main finding is that in the Nordic cohort, long-term
outcome in JIA can be predicted, with acceptable sensi-
tivity and specificity, using only a handful of readily
available clinical variables.
Study cohort
Characteristics of the 440 patients in the cohort have
previously been published [11]. The study cohort consti-
tuted 423 children, after 17 patients with systemic JIA
were excluded. The median time between disease onset
and the baseline study visit was 7 (IQR 6–8) months,
Table 1 Baseline clinical characteristics as predictors of non-achievement of remission off medication in univariate logistic regression
Baseline characteristics Total
N
Remission
off medicationa
Not in remissionb OR
(95% CI)
p
Gender female, n (%) 410 106 (38.8) 167 (61.2) 0.8 (0.5–1.2) 0.334
Age at disease onset, years 410 6.3 (2.5–10.0) 5.2 (2.5–9.6) 0.9 (0.9–1.0) 0.401
Time from onset to diagnosis, months 388 1.5 (0.5–2.9) 1.7 (0.5–3.6) 1.0 (1.0–1.1) 0.152
Cumulative active joint count 410 2 (1–4) 4 (2–7) 1.1 (1.1–1.2) < 0.001
Physician’s global assessment VAS 227 0.8 (0.0–1.3) 2.0 (1.0–3.8) 3.5 (1.9–6.2) < 0.001
Polyarticular RF-positive, n (%) 410 1 (25.0) 3 (75.0) 2.1 (0.2–20.0) 0.535
Polyarticular RF-negative, n (%) 410 25 (26.9) 68 (73.1) 2.2 (1.3–3.6) 0.003
Oligoarticular, n (%) 410 107 (49.1) 111 (50.9) 0.5 (0.3–0.7) < 0.001
Psoriatic arthritis, n (%) 410 3 (50.0) 3 (50.0) 0.7 (0.1–3.4) 0.635
Enthesitis-related arthritis (ERA), n (%) 410 11 (32.4) 23 (67.6) 1.5 (0.7–3.1) 0.315
Undifferentiated arthritis, n (%) 410 19 (34.5) 36 (65.5) 1.3 (0.7–2.4) 0.336
ANA-positive, ≤ 6 years, n (%)c 397 22 (31.4) 48 (68.6) 1.6 (0.9–2.7) 0.107
Specific joint involvement, n (%)
Hip joint 409 18 (32.1) 38 (67.9) 1.5 (0.8–2.8) 0.168
Ankle joint 409 57 (31.0) 127 (69.0) 2.1 (1.4–3.1) < 0.001
Tarsal joint 409 6 (16.7) 30 (83.3) 3.8 (1.5–9.2) 0.004
Subtalar joint 409 14 (26.9) 38 (73.1) 2.0 (1.1–3.8) 0.034
Wrist joint 409 33 (30.6) 75 (69.4) 1.8 (1.1–2.9) 0.014
Finger joint 409 36 (27.7) 94 (72.3) 2.3 (1.5–3.6) < 0.001
Neck 409 9 (26.5) 25 (73.5) 2.0 (0.9–4.4) 0.085
Upper limb joints 410 67 (32.7) 138 (67.3) 1.9 (1.3–2.9) 0.001
Lower limb joints 410 144 (39.0) 225 (61.0) 1.8 (0.9–3.5) 0.073
Symmetric involvement, n (%)
Hip joints 409 5 (21.7) 18 (78.3) 2.6 (0.9–7.1) 0.067
Ankle joints 409 27 (28.4) 68 (71.6) 2.0 (1.2–3.3) 0.006
Wrist joints 409 22 (34.4) 42 (65.6) 1.4 (0.8–2.4) 0.272
Finger joints 409 13 (22.0) 46 (78.0) 2.7 (1.4–5.3) 0.002
Patient-reported outcomes
Patient’s/parent’s global assessment VAS 250 0.5 (0.0–2.2) 1.7 (0.5–3.5) 2.2 (1.4–3.4) 0.001
CHAQ score 257 0.1 (0.0–0.6) 0.5 (0.0–1.1) 2.0 (1.3–3.0) 0.002
Pain VAS 246 0.4 (0.0–3.0) 2.3 (0.5–4.2) 1.9 (1.3–2.8) 0.002
Morning stiffness for > 15 min, n (%) 314 25 (22.1) 88 (77.9) 3.6 (2.1–6.0) < 0.001
Laboratory tests
ESR mm/h 332 11.0 (6.0–18.0) 17.0 (9.5–34.0) 1.4 (1.2–1.7) < 0.001
CRP >10 mg/L, n (%) 329 12 (16.7) 60 (83.3) 3.9 (2.0–7.5) < 0.001
ANA-positive, n (%) 397 37 (33.0) 75 (67.0) 1.5 (1.0–2.4) 0.075
RF-positive, n (%) 221 5 (50.0) 5 (50.0) 0.6 (0.2–2.0) 0.376
HLA-B27 positive, n (%) 382 21 (25.9) 60 (74.1) 2.1 (1.2–3.6) 0.010
Values are the median (interquartile range, IQR), or number (percentage)
OR odds ratio, CI confidence interval, VAS visual analogue scale, CHAQ Childhood Health Assessment Questionnaire, ESR erythrocyte sedimentation rate for an
increase in 10 mm/h, CRP C-reactive protein, ANA antinuclear antibody, RF rheumatoid factor, HLA-B27 human leucocyte antigen
aInactive disease off medication for 12 months according to the preliminary Wallace criteria
bNot in remission equals non-achievement of remission off medication
cANA-positive patients ≤6 years at disease onset, with oligoarticular, polyarticular RF negative, psoriatic or undifferentiated arthritis
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Table 2 Prediction of unfavorable outcome by multivariable
modeling of baseline clinical characteristics
Coef. Std.Err
Not in remissiona N = 156
β0=-1.58 0.44
Cumulative active joint count β1=0.04 0.05
ESR mm/h β2=0.03 0.02
CRP >10 mg/L β3=-0.07 0.69
Morning stiffness > 15 min β4=1.16 0.45
Physician’s global assessment VAS β5=0.16 0.46
ANA-positive β6=1.25 0.50
HLA-B27-positive β7=1.37 0.54
Ankle joint arthritis β8=1.10 0.49
Functional disability (CHAQ), N = 141
β0=-1.68 0.35
Cumulative active joint count β1=-0.02 0.03
ESR mm/h β2=0.01 0.01
CRP > 10 mg/L β3=-0.20 0.63
Morning stiffness > 15 min β4=1.03 0.42
Physician’s global assessment VAS β5=-0.40 0.56
Finger joint arthritis β6=1.21 0.54
Pain VAS β7 = 0.77 0.40
Functional disability (PhS), N = 92
β0=-3.40 0.75
Cumulative active joint count β1=0.10 0.05
ESR mm/h β2=0.01 0.02
CRP > 10 mg/L β3=-2.06 1.28
Morning stiffness > 15 min β4=1.68 0.80
Physician’s global assessment VAS β5=-0.71 0.88
Pain VAS β6=1.30 0.64
Joint damage (JADI-A), N = 141
β0=-3.84 0.76
Cumulative active joint count β1=0.02 0.04
ESR mm/h β2=0.01 0.02
CRP > 10 mg/l β3= -0.11 0.83
Morning stiffness > 15 min β4=-0.59 0.61
Physician’s global assessment VAS β5=0.28 0.52
Finger joint arthritis β6=1.84 0.68
Older age at disease onset (years) β7= 0.16 0.07
Coef. coefficients in the logistic regression, Std.Err. standard error in the
coefficients, VAS visual analogue scale, ESR erythrocyte sedimentation rate for
an increase in 10 mm/h, CRP C-reactive protein, ANA antinuclear antibody,
HLA-B27 human leucocyte antigen
aNot in remission equals non-achievement of remission off medication
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98 (IQR 95–102) months. The median time from disease
onset to diagnosis was 1.6 (IQR 0.5–3.3) months. A total
of 280 patients (66.2%) were female, and the median age
of disease onset in the cohort was 5.5 (IQR 2.5–9.7)
years (Additional file 1: Table S1).
At the baseline study visit, 227/423 patients (53.7%)
had oligoarthritis, 94/423 (22.2%) had rheumatoid fac-
tor (RF)-negative polyarthritis, and 4/423 (1.0%) had
RF-positive polyarthritis (Additional file 1: Table S1).
The median cumulative number of active joints within
the first visit was 3 (IQR 1–6), and 381/423 patients
(90.1%) had one or more affected lower limb joints
at the baseline visit. Antinuclear antibodies (ANA)
were present in 115/410 patients (28.1%), and HLA-
B27 in 85/393 patients (21.6%) [23], presented in
Additional file 1: Table S1. None of the children had
started biologic agents before the baseline study visit,
and early medications are shown in Additional file 2:
Table S2. A total of 410/423 (96.9% of the total co-
hort) had baseline assessments and data on remission
8 years after disease onset. The corresponding numbers
were 340/423 (80.4%) for CHAQ, 199/423 (47.0%) for PhS
and 216/423 (51.1%) for JADI-A.
Correlation between baseline variables
The clinical predictor variables were analyzed with re-
spect to correlation. There was significantly positive,
moderate to strong correlation between several variables,
especially between cumulative number of active joints,
the joint-specific variables, and the polyarthritis RF-
negative category. Physician’s GA and the patient-
reported outcomes also correlated positively with each
other. The correlation structure between the predictor
variables is illustrated in Fig. 1.
Prediction of non-achievement of remission off
medication
Remission status at the final study visit was available for
410 patients. There were 166 (40.5%) children in remis-
sion without medication, while 38 (9.3%) were in remis-
sion on medication, and 206 (50.2%) were not in
remission: 244/410 children (59.5%) did not achieve re-
mission off medication. The baseline predictors of not
achieving remission off medication were analyzed by uni-
variate logistic regression and are presented in Table 1.
The following predictor variables were included in the
multivariable prediction model for non-achievement of
remission: Cumulative active joint count, ESR, CRP,
morning stiffness, physician’s GA, ANA, HLA-B27, and
ankle joint arthritis. The first five variables were chosen
a priori, and ANA, HLA-B27, and ankle joint arthritis
were the variables included through the stepwise selec-
tion method (Table 2). The model has an AUC of 0.84in the total cohort. Cross-validation yielded a median
AUC = 0.78 (IQR 0.72–0.82) in the validation sets
(Table 3). The corresponding ROC curves are shown
in Figs. 2 and 3.
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blood samples (ESR, CRP, ANA, and HLA-B27). This
model yielded an AUC = 0.76 (IQR 0.72–0.80) for
non-achievement of remission in the validation sets
(Additional file 3: Figure S1).
Prediction of functional disability and joint damage
The CHAQ score at the final study visit was available in
340 children, and 111 (32.7%) had a CHAQ score >0.
Three of the four patients with RF-positive polyarthritis
reported functional disability. For univariate logistic re-
gression results see Additional file 4: Table S3.
The prediction model for CHAQ score >0 uses cumu-
lative active joint count, ESR, CRP, morning stiffness,
physician’s GA, finger joint arthritis, and pain VAS as
variables (Table 2). The AUC of this model was 0.79 in
the total cohort, and cross validation gave a median
AUC of 0.73 (IQR 0.67–0.76) in the validation sets
(Table 3). The ROC curve for the total cohort, and valid-
ation sets are shown in Figs. 2 and 3, respectively. The
AUC for the model without blood samples was 0.72
(IQR 0.67–0.76) in the validation sets (Additional file 3:
Figure S1).
Of the 199 patients with a physical summary score, 40
(20.1%) had a score <40. Results of the univariate ana-
lysis with PhS <40 as the outcome variable are shown in
Additional file 5: Table S4. Variables included in the pre-
diction model for PhS were cumulative active joint
count, ESR, CRP, morning stiffness, Physician’s GA, and
pain VAS (Table 2). The AUC was 0.90 in the total
cohort, and cross-validation gave a median AUC = 0.74
(IQR 0.65–0.80) in the validation sets (Table 3, Figs. 2
and 3). The AUC for the model without blood
samples was 0.73 (0.66–0.79) in the validation sets
(Additional file 3: Figure S1).
The JADI-A was collected for 216 patients at the final
study visit, and 29 patients (13.4%) had joint damage
registered 8 years after disease onset. The baseline pre-
dictors of joint damage are presented in Additional file 6:
Table S5. In the prediction model, older age at disease
onset and finger joint arthritis were included in addition
to the five previously included variables (Table 2). The
AUC was 0.84 in the cohort, and the median AUC was
0.73 (IQR 0.63–0.76) in the validation sets. The results
are summarized in Table 3 and Figs. 2 and 3. WithoutTable 3 Cross-validation of the four prediction models of unfavorab
Not in remissiona Functional disability
AUC total cohort 0.84 0.79
AUC validation setsb 0.78 (0.72–0.82) 0.73 (0.67–0.76)
AUC area under the receiver operating characteristic curve, CHAQ Childhood Health
Arthritis Damage Index-Articular
aNot in remission equals non-achievement of remission off medication
bThe AUCs in the validation sets are the median AUCs with the interquartile rangeblood tests the median AUC in the validation sets
was 0.73 (IQR 0.63–0.80) (Additional file 3: Figure S1).
Other prediction models
The prediction model developed by Guzman et al. [10]
was tested in our cohort by testing the ability of their
model to predict the four outcomes described above.
The model yielded an AUC = 0.69 for prediction of not
achieving remission. For CHAQ >0, PhS <40, and JADI-
A >0 the AUCs were 0.68, 0.69, and 0.71, respectively
(Additional file 7: Figure S2).
Discussion
In the Nordic JIA cohort, we have developed and evaluated
prediction models for long-term unfavorable outcome with
acceptable sensitivity and specificity based on variables eas-
ily available at baseline, which may guide individually tai-
lored treatment. Prediction of long-term unfavorable
outcome early in the disease course may be useful in decid-
ing when to start aggressive treatment in JIA.
To our knowledge, this is the first study on long-term
prediction of well-established disease outcomes in a
prospective population-based JIA cohort. Cross-validation
analysis of model performance yielded AUCs of 0.78, 0.73,
0.74, and 0.73, for non-achievement of remission, CHAQ
>0, PhS <40, and JADI-A >0, respectively.
An important step in developing applicable prediction
models for JIA was carried out by Guzman et al. in a
Canadian JIA cohort [10]. The authors recommended
that their results should be tested in other JIA cohorts.
We were not able to reproduce the predictive ability of
their model in the Nordic JIA cohort (Additional file 7:
Figure S2). One obvious reason for the discrepancy
could be that Guzman’s model is constructed to predict
severe disease course, and not per se, any of the four
pre-established, validated adverse outcomes that we
assessed. Other reasons may be differences in the
population-based approach, cohort composition, or eth-
nicity, or overfitting of models to the cohort.
The primary goal in the treatment of children with JIA
is to achieve remission off medication, and the main im-
plication of the current study is that prediction models
may be useful in guiding decisions about treatment.
Previous studies have indicated that the disease course
may be modified by starting appropriate treatment earlyle long-term outcome in the Nordic JIA cohort
(CHAQ) Functional disability (PhS) Joint damage (JADI-A)
0.90 0.84
0.74 (0.65–0.80) 0.73 (0.63–0.76)
Assessment Questionnaire, PhS Physical Summary Score, JADI-A Juvenile
of the 100 constructed models
Fig. 2 Receiver operating characteristic (ROC) curves for the four
unfavorable clinical outcomes in the total cohort. Non-achievement
of remission off medication; CHAQ, Childhood Health Assessment
Questionnaire; PhS, Physical Summary Score; JADI-A, Juvenile
Arthritis Damage Index-Articular
Fig. 3 Receiver operating characteristic (ROC) curves for the four unfavorab
mean ROC curves for the 100 different realizations of the partitioning of th
in remission. b Childhood Health Assessment Questionnaire (CHAQ) >0. c P
Index-Articular (JADI-A) >0
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treat-to-target strategy including shared decision-making
with well-informed children and parents is currently rec-
ommended [6, 9]. Even with promising advances in
using gene expression profiles and biomarkers as predic-
tors of treatment response and flare risk [26–29], the
practical value of prediction based on a handful of read-
ily available clinical variables cannot be understated.
The main strengths of our study are the use of validated
outcome measures, the simplicity of the models, and the
strict cross-validations. The use of validated outcomes is
called for in reports on prognosis in JIA [3, 30, 31]. Model
simplicity is ensured through the model construction
method, where the main variables in the preliminary
Wallace criteria of remission are included in the models a
priori [15, 22]. The additional variables that were included
in our models have independently been associated with
adverse outcomes in previous studies [4, 23, 32–36].
The model performance was assessed using cross-
validations, where predictions were performed on valid-
ation sets that were completely separate from the data used
to construct the models. The 100 repeated model construc-
tions and evaluations prevent overfitting the data. Despitele clinical outcomes in the validation sets. The colored lines are the
e cohort into training sets and validation sets (thin gray curves). a Not
hysical Summary Score (PhS) <40. d Juvenile Arthritis Damage
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obtained acceptable predictive ability. The robustness and
applicability of the prediction rules are emphasized by the
fact that when the analyses were repeated without any
blood tests, the performance was similar. An online calcula-
tor based on our models is available at the web-page http://
predictions.no. An iOS app is also designed, and the test
versions are available on request.
One of the limitations of our study is that for some of
the patients, the baseline study visit scheduled 6 months
after disease onset was not the first clinical visit. Some
children had therefore already started treatment, mostly
with nonsteroidal anti-inflammatory drugs (NSAIDs) or
intraarticular corticosteroids, and were not treatment
naïve when the predictor variables were assessed. This
baseline time point, however, allowed use of the cumula-
tive active joint count during the first 6 months of the dis-
ease, which is an important measure of early disease
severity in line with the International League of Associa-
tions for Rheumatology (ILAR) criteria. A limitation is
also that the primary outcome, non-achievement of remis-
sion off medication, is defined as inactive disease for more
than 1 year, and this outcome does not necessarily reflect
the disease course during the whole 8-year period. In
addition, JADI-A is a rather crude measure of joint dam-
age, and future predictive studies should therefore include
imaging in joint damage assessment. Finally, the treatment
given during the disease course may have altered the dis-
ease outcome, even though biologic medications were not
generally available in the beginning of the study period in
1997. The natural history of JIA disease course without
treatment is clearly impossible and unethical to study.
Conclusion
We have developed statistical models for predicting non-
achievement of remission off medication, functional dis-
ability, and joint damage in children with JIA. The models
are easy to use, and may provide a valuable tool to aid
early treatment decisions on the need for DMARDs in-
cluding biologic agents if validation in other JIA cohorts
and across ethnicities can confirm our results [37]. We en-
courage further testing of our models before the applic-
ability can be generalized and recommended.
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